White House IVF Announcement — Smoke, Mirrors & Missed Opportunities

What happened to “free IVF for all” that Trump promised?

Summary: The White House announced a partnership with EMD Serono to sell three IVF drugs—GONAL-F, Ovidrel, and Cetrotide—directly to patients at discounted prices through a new federal website, TrumpRx.gov. The plan also introduces a voluntary employer fertility-benefit option and promises faster FDA reviews of new fertility drugs, but it does not require insurance coverage or guarantee IVF access, instead relying on private drug discounts and optional employer participation

Core Takeaway: Families don’t need a coupon — they need coverage. A $2,200 discount on medication doesn’t make IVF accessible; true access would mean a $22,000 reduction through required insurance coverage and that isn’t the case here. The federal government had the power to act and chose politics over people. States must continue to lead by passing laws that protect IVF, require insurance coverage, and ensure every family has the freedom to build their future.

Breaking Down the Facts: Talking Points

Fertility Coverage Is Essential Healthcare — Not a Luxury.

Fertility care isn’t optional — it’s essential health care. When labeled “elective”, as the White House’s IVF announcement indicates, it becomes as inaccessible as glasses or dental care for millions. No family should have to treat the ability to grow their family as a luxury item.

This Isn’t Protection or Progress — It’s Political Theater.

The White House announcement is not an insurance mandate and does not protect IVF. It creates an optional benefit employers may offer, treating fertility care like vision or dental — two benefits many Americans skip because they can’t afford them. And, by placing optional benefits outside of medical insurance, the White House could be placing fertility health care out of the protection of the Affordable Care Act, its nondiscrimination protections and its prohibition on lifetime maximums. Real reform requires insurers to cover IVF, as proposed in multiple federal bills that Republican leadership has repeatedly blocked. Two states have already tried the “may offer” approach — and one had to return to mandates to make care accessible, while the other state’s offer mandate has floundered. Why? Because a “may offer” approach does not actually work.

Elective Models Hurt Small Businesses and Families.

The IVF announcement places the burden solely on small and medium businesses. Money doesn’t grow on trees, and placing the burden on hardworking American business owners to decide whether to offer fertility coverage is both unrealistic and unfair. With rising operating costs, most small and medium businesses can’t afford to offer these benefits voluntarily — even if they want to. This guarantees inequity and limits access to only the largest employers, making it even harder for small businesses to stay competitive in wages and benefits. Small businesses employ nearly half of the American workforce (U.S. Chamber of Commerce).

The Only Winners Are Politicians and Drug Companies.

Families aren’t saving — corporations are. The “discount” is a limited saving on three drugs, manufactured by EMD Serono, available only through a government website that requires patients to hand over deeply personal medical information. That’s alarming from a data-privacy standpoint — and what happens during government shutdowns like the one we’re under now?

Medication access shouldn’t depend on whether a website stays funded or a private deal. This isn’t freedom; it’s control.

A Discount Wrapped in a Deal — Not Affordability.

The discount now extends to three drugs — GONAL-F, Ovidrel, and Cetrotide — but patients only benefit if their doctor prescribes these medications. IVF protocols are highly individualized; not every patient needs all of these drugs. This structure excludes thousands of patients and forces treatment decisions to fit a political deal, not medical science.

This agreement isn’t about helping families — it’s about helping a foreign pharmaceutical giant. In exchange for offering “discounted” drugs through a federal purchasing site, EMD Serono (the U.S. arm of Merck KGaA, Germany) secured a special arrangement to bypass import tariffs on its products. That means the White House traded away economic leverage in return for a headline and handed one company near-total control over the nation’s IVF medication market.

This isn’t healthcare reform; it’s a back-room bargain that creates a monopoly, rewards political allies, and treats fertility patients as leverage.

These Solutions Further Stigmatize American Families.

We want American families in the driver’s seat of their ability to grow or start their families, not employers or politicians. No one should have to rely on their boss’s approval, company policy, or political ideology to decide whether they can have children. Treating fertility care as optional keeps it out of reach for millions and reinforces outdated notions that family building through medical assistance is less valid than any other path to parenthood.

Real freedom means being able to decide when and how to build your family — with access to affordable, science-based fertility care, not government “deals”, gimmicks or employer permission.

“Ethical Fertility” Customization = Discrimination.

Allowing employers or benefit managers to selectively include or exclude certain treatments — such as only covering “restorative reproductive medicine” — opens the door to ideologically driven healthcare. No one should have to rely on an employer’s personal or religious beliefs to access scientifically proven fertility care. This is also political calculus, allowing the White House to sidestep the Affordable Care Act — the very policy they continue trying to dismantle.

This Lets Insurance Companies Off the Hook.

Voluntary models allow insurers to keep avoiding responsibility for fertility care while experiencing record profits for shareholders, while the people trying to start or grow their families suffer. The solution isn’t employer choice — it’s systemic reform. Insurers must be required to cover fertility treatment the same way they cover any other essential medical care.

The Federal Government Had the Power to Act — and Chose Not To.

In 2024, the Right to IVF Act was introduced to guarantee nationwide access to IVF and fertility treatment. It was blocked by Republicans — despite overwhelming public support. Instead of requiring coverage, this administration chose a voluntary, piecemeal plan that will not address affordability or access, so it appears as a “win” in their column while knowing it isn’t actually reform. If policymakers truly want to address declining birth rates, they must invest in real, comprehensive fertility coverage — not political gimmicks.

Questions? Contact statestrongcoalition@gmail.com | statestrong.org